Pre-Clinical to Clinical Trials Track

 

 

As new technologies and personalized vaccines become the norm, the dynamic of clinical trials has to evolve.

This focused clinical development conference will allow you to showcase your services to those who are looking to run new trial models, need support in choosing and gaining approval for different clinical endpoints and want to understand how to get the best out of the information collected.

 

 

Who Sponsors?

 

 

• CROs
• OEMs / Equipment Manufacturers
• Platform Technology Providers
• Big Pharma
• Biotechs

Who Attends

 

 

• Pharma
• Biotechs
• National and International Government
• Academics And Research Institutions

Job Titles

 

 

• CEO / CSO / COO
• CMO / Head of Scientific Affairs
• Head of (Pre-) Clinical Development
• Head of Clinical Trial Management / Operations
• Head of R&D

 

 

2018 AGENDA

 

Clinical Development, Tuesday 30 October 2018

Opening Plenary Session

Dr Martin Friede
09:40

Short morning break followed by session tracks

Clinical Development
10:00

Chair’s opening remarks

Clinical Development

Clinical Development

Clinical Development
10:05

Moving from pre-clinical to clinical

Senior representative, Viroclinics
 
Clinical Development
10:35

Early and late phase clinical trial design conundrums Use of surrogate endpoints, differential efficacy / safety in diverse populations, accurate measures of exposure

Senior representative, PRA Health Sciences
11:05

Morning Networking Break

Clinical Development
12:35

Adjuvants: Their optimal delivery and how they advance into clinical evaluation and assessment of their performance


 
Sarah Gilbert
Clinical Development
13:05

Clinical development of emerging pathogen vaccines using adenoviral vector platform technology

13:35

Networking Lunch & Poster Session

Dr Adrian Wildfire
Clinical Development
15:05

Unplanned parainfluenza virus infection on an isolation ward – A case study

Title subject to change
Dr Dimitri Diavatopoulos
Clinical Development
15:35

Identifying knowledge gaps and combinational approaches to gain an effective model for Pertussis

Prof Robert Read
Clinical Development
16:05

A human challenge model of Bordetella pertussis infection, for the testing of novel whooping cough vaccines

Dr Michael Makanga
Clinical Development
16:35

World Bank collaboration and its capacity for vaccine trials in emerging countries (strategy and plans)

Professor Hanna Nohynek
Clinical Development
17:05

Challenges in Phase IV studies and register based impact research

Chair closing remarks of day one followed by Drinks Reception

last published: 18/May/18 16:15

Clinical Development, Wednesday 31 October 2018

10:40

Morning Networking Break

12:50

Afternoon Networking Lunch

AFTERNOON PLENARY TALKS

Dr Giovanna Zanoni
14:00

Status of vaccine confidence around the world

  • Social and political factors that can affect uptake of vaccines
  • How can we better educate the public the benefits of immunisation?
  • How can public health institutions, government and vaccine developers help with building a coherent story
  • AEFI surveillance and risk communication
  • Are we overlooking the power of social media?
Fred Zepp, Medical Director and Chairman of the Department of Paediatrics, University Medicine Mainz
Dr Helen Bright
14:50

Flumist vaccine effectiveness – It’s return and the real story

  • Questions over the effectiveness of the live attenuated vaccine
  • Why it lost its recommendation
  • The journey, investigation and trial data to rectify this
Dr Rino Rappuoli

Chair’s closing remarks and close of congress

last published: 18/May/18 16:15

Sign Up for Event Updates